Why complement-blocking drugs work differently in NMOSD, MOGAD, MS

Credibility

Interest

Key Takeaway

Different immune “complement” patterns in the brain help explain why treatments that block this system work well for NMOSD but may help less or only in some cases of MOGAD and MS.

What They Found

Researchers looked at brain tissue from people with NMOSD, MOGAD, and MS to see where parts of the complement system were sticking to cells. In NMOSD (a disease that mainly attacks support cells called astrocytes), all three complement markers made a clear rim or rosette pattern around blood vessels, matching the severe damage seen there. In MOGAD (which mainly targets the myelin protein MOG), most samples had one complement marker (C4d) around small veins, but a later-stage marker (C9neo) was only strongly present in some people; when C9neo was high, the protective cells that make myelin (oligodendrocytes) were lost. In MS, only the early marker C4d was clearly found on myelin near active lesion edges, and complement signals were stronger in cases that ended sooner after disease worsening. Overall, each disease showed a distinct complement “fingerprint,” suggesting they cause damage in different ways.

Who Should Care and Why

MS patients and caregivers should know this because it helps explain why some immune-blocking drugs work better for certain diseases—think of it like different locks needing different keys. People with NMOSD benefit a lot from drugs that block complement because the complement system is strongly involved in its damage pattern. For MOGAD, some people show signs of complement-driven damage while others do not, so complement-blocking treatments might help only a subgroup—like choosing a tool that fits only some bolts. For MS, complement seems involved mainly near active lesion edges and in more aggressive cases, so blocking complement may be less consistently helpful than other MS treatments. Clinicians can use this kind of information to guide testing and tailor treatments more precisely, and caregivers can use it to ask targeted questions about why a therapy is recommended.

Important Considerations

This study looked at brain tissue after illness (autopsy and biopsy), so findings show what happened at that moment and may not reflect early or changing stages in living patients. The presence or absence of complement markers does not by itself prove that blocking complement will always help—clinical trials are needed to confirm benefit. Also, MOGAD showed two patterns (less destructive and more destructive), meaning not all patients with the same diagnosis will respond the same way to complement-targeting treatments.

Categories:

MS Diagnostics Early Research MS Genetics

Article Topics:

C4dC9neoComplementMOGADMSNMOSD

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Acta neuropathologica often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News